Macrophage inflammatory protein-3 beta enhances IL-10 production by activated human peripheral blood monocytes and T

H D Byrnes1, H Kaminski, A Mirza

  • 1Department of Immunology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.

Insights

Human macrophage inflammatory protein-3 beta (MIP-3 beta) significantly boosts anti-inflammatory cytokine IL-10 production in immune cells. This chemokine uniquely modulates inflammation by enhancing IL-10, impacting immune responses.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Interleukin-10 (IL-10) is a key anti-inflammatory cytokine.
  • Macrophage inflammatory protein-3 beta (MIP-3 beta) is a chemokine that binds to CCR7.
  • The role of MIP-3 beta in modulating cytokine production is not fully understood.

Purpose of the Study:

  • To investigate the effect of MIP-3 beta on IL-10 production in human peripheral blood mononuclear cells (PBMCs).
  • To determine if MIP-3 beta influences other cytokine productions, such as IL-12 p40, TNF-alpha, and IFN-gamma.
  • To explore the mechanism by which MIP-3 beta modulates cytokine production.

Main Methods:

  • Human PBMCs, monocytes, and T cells were stimulated with LPS or PHA.
  • MIP-3 beta and other chemokines were added to cell cultures.
  • Cytokine levels (IL-10, IL-12 p40, TNF-alpha, IFN-gamma) were measured.
  • CCR7 mRNA expression and intracellular calcium mobilization were assessed.

Main Results:

  • MIP-3 beta significantly enhanced IL-10 production in LPS- and PHA-stimulated PBMCs in a dose-dependent manner.
  • MIP-3 beta inhibited IL-12 p40 and TNF-alpha production by monocytes and IFN-gamma production by T cells.
  • These effects were reversed by anti-IL-10 antibodies.
  • MIP-3 beta's action correlated with CCR7 expression and calcium mobilization.

Conclusions:

  • MIP-3 beta directly acts on human monocytes and T cells to enhance IL-10 production.
  • MIP-3 beta uniquely modulates inflammatory activity by increasing anti-inflammatory IL-10.
  • This finding suggests a novel therapeutic potential for MIP-3 beta in inflammatory diseases.